

Thyroid GuidePx[®]

The first genomic classifier for papillary thyroid cancer.



Unlike any other test.


**Bethesda V/VI
papillary thyroid cancer**

Thyroid GuidePx[®]

Bethesda III/IV

Other molecular tests are only validated for indeterminate thyroid nodules.

Identifies low risk PTC with >96% specificity.



Confidently identify low risk patients.
Avoid overtreatment in appropriate candidates for conservative management.

Simple.

1




Test can be performed on fine needle aspirate or on surgical specimen.

2



We perform next generation sequencing, measuring the expression of 82 prognostic genes.

3



Our proprietary algorithm, built using advanced machine learning and backed by clinical research, identifies the molecular subtype.

4



You get a test report describing biological features and recurrence risks.

Cost Effective.

Thyroid GuidePx[®] done on FNA refines selection of patients selected for lobectomy. Thyroid GuidePx[®] done post-lobectomy reduces the % of patients that require a completion thyroidectomy. Increases quality adjusted life years (QALYs) per patient. Cost savings compared to standard of care.